Compare EHang Holdings Ltd - ADR (EH) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Cassava Sciences Inc — how do they compare? EHang Holdings Ltd - ADR trades at $4.09 (market cap $309.45M), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: EHang Holdings Ltd - ADR is far larger — about 7.9× Cassava Sciences Inc's market cap, and EHang Holdings Ltd - ADR is more actively traded (765,799 versus 759,018). Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and Cassava Sciences Inc for 37 Days on average.
| EH | FLNA | |
|---|---|---|
Market Cap | $309.45M | $39.40M |
Volume | 765,799 | 759,018 |
Sector | Industrials | Health |
52-Week High | $18.94 | $4.64 |
52-Week Low | $4.03 | $0.68 |
Typical Hold Time | 46 Days | 37 Days |
Enterprise Value | $261.14M | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $275.98 million on $417.98 million revenue in 2025, with negative profit margins and ROE. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a volatile backdrop.
The outlook remains challenging due to persistent losses and regulatory scrutiny, though the company's cash position of $1.12 billion provides some buffer. Investment opportunities hinge on successful commercialization of eVTOL technology, while risks include execution missteps, intense competition, and ongoing legal probes. The stock is suitable only for high-risk investors betting on long-term AAM adoption.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
